Acute lymphoblastic leukemia（ALL）is the most common hematologic malignancy in children. The prognosis of ALL in pediatric patients has significantly improved in recent years. However，for pediatric popu⁃ lation with relapsed/refractory ALL，conventional chemotherapy has a low remission rate and provides no promising prognosis. With the emergence of immunotherapy，immunotherapies targeting ALL antigen ⁃associated monoclonal antibodies and chimeric antigen receptor T cells have shown to be effective against ALL，significantly improving the prognosis in patients with relapsed/refractory ALL. In this article，we review the immunotherapy for ALL in children.